The greatest risk of grade 3–4 PAEs in patients with head and neck cancer was linked to anti-PD1 plus targeted therapy drug, which had significant differences with the other interventions except for anti-PD1 plus chemotherapy. Here, PDCD1 is linked to head and neck cancer.